Search results
Found 18026 matches for
Co-PACT Team
Co-Pact involves a number of people from different organisations, click 'read more' to find out who is involved!
Selected PPiP2 study documents for researchers
Click on the desired document to start the download. If you cannot find a document you need please email the central research team at ppip@psych.ox.ac.uk
About Us
SINAPPS stands for Study of Immunology in Antibody Positive Psychosis. We are a research group formed of collaborating Universities in the UK, investigating the role of autoimmune antibodies as a cause of psychosis.
Studies
Below is a list of SINAPPS Group studies both current and closed
Get Involved
We are offering tests for antibodies in people experiencing psychosis symptoms through the Prevalence of Pathogenic Antibodies in Psychosis 2 study (PPiP2)
Advice for Clinicians
The findings from previous studies suggest that approximately 5-10% of patients presenting to NHS Early Intervention in Psychosis services are positive for autoantibodies against neuronal targets (Lennox et al, 2016, Zandi et al, 2011).
Resources and Glossary
Here you will find a list of resource links and and a glossary related to our research.
Study of Immunology in Antibody Positive Psychosis 1 (SINAPPS1) 2015 - 2017
SINAPPS1 was as open label study of the feasibility of plasmapheresis or intravenous immunoglobulin, combined with corticosteroids, in patients with acute psychosis and anti-neuronal membrane auto-antibodies. The aim of SINAPPS1 was to investigate delivering immunotherapy to this patient group in general hospital settings.
SINAPPS2 Trial
SINAPPS2 is a phase II ongoing clinical trial aiming to test the efficacy and safety of immunotherapy (intravenous immunoglobulin combined with rituximab) vs placebo treatment in people with acute symptoms of psychosis and anti-neuronal membrane antibodies.
SINAPPS2 Trial Procedures
Please note that the following information, while true and detailed, is not exhaustive of the study procedures. A full Participant Information Sheet will be given to potential trial participants and a researcher and neurologist will be available to discuss the details of the trial before an offer of participation.
Prevalence of Pathogenic Antibodies in Psychosis 1 (PPiP1) 2013-2014
PPiP1 study aimed to investigate the prevalence of antibodies against neuronal cell surface targets in patients experiencing their first episode of psychosis in comparison with healthy participants in the control group. The immune system normally controls our ability to fight infection. If the immune system goes wrong it may cause diseases known as ‘autoimmune’ diseases. These diseases involve autoimmune ‘antibodies’ that target healthy parts of the body, instead of infections. We can detect these antibodies using blood tests. We are specifically interested in antibodies that may be the cause of symptoms of psychosis or schizophrenia. During the study we worked with NHS Mental Health services across England to investigate the prevalence of these antibodies in people with first episode of psychosis.
Prevalence of Pathogenic Antibodies in Psychosis 2 (PPiP2)
The PPiP2 study aims to investigate the prevalence of autoimmune antibodies in patients with psychosis and identify people with psychosis and anti-neuronal membrane antibodies to take part in the SINAPPS2 trial.
PPiP2 Study
PPiP2 is a cross-sectional study conducted in over 40 NHS mental health trusts, across England and Scotland. It uses live-based assay to test serum of study participants with psychosis for NMDAR, LGI1, GABA-A and CASPR2. PPiP2 will continue to recruit study participants until the end of November 2027.
Press Enquiries
For all press enquiries, please contact
PPiP2 Research Teams in participating NHS Trusts
Please email researchers in a NHS trust where you receive mental health care. If your NHS trust is not in the list email ppip@psych.ox.ac.uk